VIR
HEALTHCAREVir Biotechnology Inc
AI Insight
What's Moving VIR Today?
No stock-specific AI insight has been generated for VIR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.16$11.66
$10.16
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-3.13
Dividend Yield—
Dividend / Share—
ROE-47.7%
Profit Margin—
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding168.7M
VIR News
25 articles- Vir Biotechnology (VIR) director Coughlin reports zero share ownershipStock Titan·Jun 11, 2026
- Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsYahoo Finance·Jun 10, 2026
- Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?Insider Monkey·Jun 7, 2026
- Vir Biotechnology (VIR) director receives RSU and stock option grantsStock Titan·May 29, 2026
- Vir Biotechnology, Inc. Announces Changes in Board and Audit Committee, Effective May 26, 2026www.marketscreener.com·May 28, 2026
- How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment StoryYahoo Finance·May 24, 2026
- Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyThe Motley Fool·May 23, 2026
- Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026Yahoo Finance·May 18, 2026
- Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 MillionMotley Fool·May 18, 2026
- Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million SharesMotley Fool·May 17, 2026
- Vanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIRMarketBeat·May 15, 2026
- Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New ForecastsYahoo Finance·May 11, 2026
- A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline ProgressYahoo Finance·May 10, 2026
- Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.Motley Fool·May 9, 2026
- Vir Biotechnology Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial ResultsBioSpace·May 7, 2026
- Vir Biotechnology, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Vir (VIR) Q1 2026 Earnings Call TranscriptMotley Fool·May 6, 2026
- Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare ConferenceYahoo Finance·May 5, 2026
- Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·May 4, 2026
- Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii ArbitrationYahoo Finance·Apr 29, 2026
- Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsYahoo Finance·Apr 23, 2026
- Vir Biotechnology (VIR) Posts 80.98% Year-To-Date GrowthYahoo Finance·Apr 22, 2026
- Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?Yahoo Finance·Apr 20, 2026
- Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000The Motley Fool·Apr 12, 2026
All 25 articles loaded
Price Data
Open$9.39
Previous Close$10.16
Day High$10.18
Day Low$9.39
52 Week High$11.66
52 Week Low$4.16
52-Week Range
$4.16$11.66
$10.16
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-3.13
Dividend Yield—
Dividend / Share—
ROE-47.7%
Profit Margin—
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding168.7M
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—